
Goldman Sachs BDC, Inc.
GSBDGoldman Sachs BDC, Inc. (GSBD) is a business development company that primarily invests in middle-market companies across various industries. Managed by Goldman Sachs Asset Management, GSBD focuses on providing debt and equity financing solutions to support growth and strategic initiatives for its portfolio companies. The firm aims to generate income and capital appreciation for its shareholders through its targeted investment strategies.
Dividend History
Investors can expect a dividend payout of $0.32 per share, scheduled to be distributed in 4 days on January 27, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 27, 2026 | $0.32 | 2025-12-31 | 2025-12-31 |
| December 15, 2025 | $0.04 | 2025-11-28 | 2025-11-28 |
| October 28, 2025 | $0.32 | 2025-09-30 | 2025-09-30 |
| October 28, 2025 | $0.16 | 2025-09-30 | 2025-09-30 |
| September 15, 2025 | $0.03 | 2025-08-29 | 2025-08-29 |
Dividends Summary
- Consistent Payer: Goldman Sachs BDC, Inc. has rewarded shareholders with 53 dividend payments over the past 11 years.
- Total Returned Value: Investors who held GSBD shares during this period received a total of $20.03 per share in dividend income.
- Latest Payout: The most recent dividend of $0.32/share was paid 39 days ago, on December 15, 2025.
- Yield & Schedule: GSBD currently pays dividends quarterly with an annual yield of 8.94%.
- Dividend Growth: Since 2015, the dividend payout has decreased by 28.9%, from $0.45 to $0.32.
Company News
The article discusses four stocks with high dividend yields that Wall Street analysts are cautious about, including National Storage Affiliates Trust, CNA Financial, Cricut, and Goldman Sachs BDC.
Goldman Sachs BDC's share price appears to have stabilized after a sell-off in May. Read more to see why I'm bullish on GSBD stock.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wedbush analyst David Nierengarten downgraded the rating for Ikena Oncology, Inc. (NASDAQ:IKNA) from Outperform to Neutral, while slashing the price target f...
High-yield stocks have underperformed recently. Click here to find out why and how we have managed to outperform despite the headwinds.
Related Companies









